Population Pharmacokinetic Model for Adherence Evaluation Using Lamivudine Concentration Monitoring

被引:13
|
作者
Zhang, Chao [1 ]
Denti, Paolo [1 ]
van der Walt, Jan-Stefan [1 ]
Ren, Yuan [1 ]
Smith, Peter [1 ]
Karlsson, Mats O. [2 ]
McIlleron, Helen [1 ]
机构
[1] Univ Cape Town, Dept Med, Div Clin Pharmacol, ZA-7925 Cape Town, South Africa
[2] Uppsala Univ, Dept Pharmaceut Biosci, Uppsala, Sweden
基金
英国惠康基金;
关键词
lamivudine; population pharmacokinetics; NONMEM; CHILDREN; TUBERCULOSIS; RIFAMPICIN;
D O I
10.1097/FTD.0b013e31825c6067
中图分类号
R446 [实验室诊断]; R-33 [实验医学、医学实验];
学科分类号
1001 ;
摘要
Background: Interpretation of antiretroviral drug concentration measurements could be aided by information about adherence to recent doses. We developed a population pharmacokinetic model of lamivudine in young children to propose reference lamivudine concentrations for evaluation of adherence to recent treatment doses. Methods: The steady state pharmacokinetics of lamivudine were evaluated in 68 young HIV-infected children receiving antiretroviral treatment twice daily. A population pharmacokinetic analysis was conducted using NONMEM 7. Results: A 2-compartment model with transit absorption best described lamivudine pharmacokinetics. After adjustment for maturation and body weight (using allometric scaling), the variability of clearance was small, hence simulations could accurately predict lamivudine concentrations. Higher lamivudine trough concentrations were detected before the morning dose, possibly owing to slower overnight clearance. Reference values for lamivudine concentrations that can be used to evaluate adherence to recent doses are proposed. Conclusions: Lamivudine concentration measurement can be used to assess recent treatment adherence.
引用
收藏
页码:481 / 484
页数:4
相关论文
共 50 条
  • [31] A Population Pharmacokinetic/Pharmacodynamic Model of Methotrexate and Mucositis Scores in Osteosarcoma
    Johansson, Asa M.
    Hill, Nicola
    Perisoglou, Martha
    Whelan, Jeremy
    Karlsson, Mats O.
    Standing, Joseph F.
    THERAPEUTIC DRUG MONITORING, 2011, 33 (06) : 711 - 718
  • [32] Population pharmacokinetic model of PI-88, a heparanase inhibitor
    Susan F. Hudachek
    S. Gail Eckhardt
    Barbara Hicks
    Daniel L. Gustafson
    Cancer Chemotherapy and Pharmacology, 2010, 65 : 743 - 753
  • [33] A population pharmacokinetic model to predict oxypurinol exposure in patients on haemodialysis
    Daniel FB Wright
    Matthew P. Doogue
    Murray L Barclay
    Peter T Chapman
    Nicholas B Cross
    John H Irvine
    Lisa K Stamp
    European Journal of Clinical Pharmacology, 2017, 73 : 71 - 78
  • [34] Phenobarbital in intensive care unit pediatric population: predictive performances of population pharmacokinetic model
    Marsot, Amelie
    Michel, Fabrice
    Chasseloup, Estelle
    Paut, Olivier
    Guilhaumou, Romain
    Blin, Olivier
    FUNDAMENTAL & CLINICAL PHARMACOLOGY, 2017, 31 (05) : 558 - 566
  • [35] Population pharmacokinetic analysisof lamivudine, stavudine and zidovudine in controlled HIV-infected patients on HAART
    Panhard, Xaviere
    Legrand, Mayeule
    Taburet, Anne-Marie
    Diquet, Bertrand
    Goujard, Cecile
    Mentre, France
    EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 2007, 63 (11) : 1019 - 1029
  • [36] External Evaluation of Risperidone Population Pharmacokinetic Models Using Opportunistic Pediatric Data
    Karatza, Eleni
    Ganguly, Samit
    Hornik, Chi D.
    Muller, William J.
    Al-Uzri, Amira
    James, Laura
    Balevic, Stephen J.
    Gonzalez, Daniel
    FRONTIERS IN PHARMACOLOGY, 2022, 13
  • [37] Paroxetine: population pharmacokinetic analysis in late-life depression using sparse concentration sampling
    Feng, Y
    Pollock, BG
    Ferrell, RE
    Kimak, MA
    Reynolds, CF
    Bies, RR
    BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2006, 61 (05) : 558 - 569
  • [38] Population pharmacokinetic analysisof lamivudine, stavudine and zidovudine in controlled HIV-infected patients on HAART
    Xavière Panhard
    Mayeule Legrand
    Anne-Marie Taburet
    Bertrand Diquet
    Cécile Goujard
    France Mentré
    European Journal of Clinical Pharmacology, 2007, 63 : 1019 - 1029
  • [39] EVALUATION OF POPULATION (NONMEM) PHARMACOKINETIC PARAMETER ESTIMATES
    VOZEH, S
    MAITRE, PO
    STANSKI, DR
    JOURNAL OF PHARMACOKINETICS AND BIOPHARMACEUTICS, 1990, 18 (02): : 161 - 173
  • [40] Development of a population pharmacokinetic model of pyrazinamide to guide personalized therapy: impacts of geriatric and diabetes mellitus on clearance
    Kim, Ryunha
    Jayanti, Rannissa Puspita
    Lee, Hongyeul
    Kim, Hyun-Kuk
    Kang, Jiyeon
    Park, I-Nae
    Kim, Jehun
    Oh, Jee Youn
    Kim, Hyung Woo
    Lee, Heayon
    Ghim, Jong-Lyul
    Ahn, Sangzin
    Long, Nguyen Phuoc
    Cho, Yong-Soon
    Shin, Jae-Gook
    cPMTb
    FRONTIERS IN PHARMACOLOGY, 2023, 14